More cohesive.
More form stable.2-4
Bench Testing Comparing Gel Cohesivity of Natrelle INSPIRA® Cohesive, Mentor® MemoryGel®, and Sientra® Style 106 Breast Implants ex Vivo (Sientra® style 107 was not available for testing)
51% more cohesive than Mentor® MemoryGel®.
37% more cohesive than Sientra® style 106.
Less elastic deformation
=
More cohesive2,†
In vivo significance has not been established.
Methodology Breast implant gel was measured for material properties using the BTC‑2000 ™. The BTC‑2000 ™ applies a controlled vacuum, or negative pressure, to the gel while measuring the dynamic response of material deformation using a synchronized target laser. The gel for each device (n = 8 per group) was tested at 3 sites, all at or near the apex of the implant (anterior side). From those measurements, the gel cohesivity was calculated and the relative change was determined.

Bench Testing Comparing Gel Cohesivity of Natrelle INSPIRA® Cohesive, Mentor® MemoryGel®, and Sientra® Style 106 Breast Implants ex Vivo (Sientra® style 107 was not available for testing)
47% more form stable than Mentor® MemoryGel®.
28% more form stable than Sientra® style 106.
Lower overall changes in
height and projection
=
More form stable4,5,‡
In vivo significance has not been established.
Methodology Breast implant devices (n = 6 per group) were placed in a horizontal orientation on a sliding stage; the width and maximum projections of the implants were measured using fixed calipers. The devices were then placed in a vertical‑supported orientation using a 90° angle, and the width and maximum projections were measured again. From those measurements, the retention of dimension was calculated and the relative change was determined.
Designed to maintain
upper pole fullness.
The highly cohesive gel in Natrelle
INSPIRA® Cohesive is designed to
prevent downward movement, helping
the implant maintain a form-stable
upper pole.4,§
§Based on implant performance testing; clinical
significance has not been established.
Even when the implant
is held upright, it retains
its shape.
Cohesive Gel
In vivo significance
has not been established.
Natrelle INSPIRA® Cohesive
Form-stable upper pole
High gel fill ratio
Highly cohesive gel
Go gummy and get recognized.
Send us your before & after
breast reconstruction photos.
Your case studies could be selected
by a peer-reviewed committee
for inclusion in an upcoming
journal supplement, as well as
other publications and
promotional materials.
STEP 1
SELECT THE RIGHT PATIENTS.
  • One-stage reconstruction
  • Two-stage reconstruction
  • Revision reconstruction

STEP 2
TRACK KEY CHECKPOINTS
WITH PHOTOS.
  • Preoperative
  • First stage (optional)
  • 3 months post-op

STEP 3
EMAIL PATIENT RESULTS.
  • Send photos, consent forms, and additional information to GoGummy@Allergan.com
  • Submit as many cases as you like
Contact your Allergan sales
representative for program
details, including ordering and
entry information.
Ready to go gummy?
Natrelle INSPIRA® Silicone-Filled Breast Implants Important Information
Indications
Indicated for women for the following:
Important Safety Information
Contraindications
Breast implant surgery should not be performed in:
Warnings
Precautions
Safety and effectiveness have not been established in patients with the following:
Adverse Events

Key adverse events are reoperation, implant removal with or without replacement, implant rupture, and capsular contracture Baker Grade III/IV.

Other potential adverse events that may occur with breast implant surgery include: asymmetry, breast pain, breast/skin sensation changes, capsular calcification, delayed wound healing, hematoma, hypertrophic scarring/scarring, implant extrusion, implant malposition, implant palpability/visibility, infection, nipple complications, redness, seroma, swelling, tissue/skin necrosis, wrinkling/rippling.

For more information see the full Directions for Use at www.allergan.com/labeling/usa.htm. To report a problem with Natrelle INSPIRA® Breast Implants, please call Allergan at 1‑800‑433‑8871.

Natrelle INSPIRA® Breast Implants are available by prescription only.

References: 1. Data on file, Allergan. 2. Data on file, Allergan, August 31, 2016; Study Report MD16064-DV. 3. Natrelle® Silicone-Filled Breast Implants and Natrelle INSPIRA® Breast Implants: Smooth & BIOCELL® Texture Directions for Use, 2016. 4. Data on file, Allergan, September 6, 2016; Study Report MD16062-DV. 5. Data on file, Allergan, August 1, 2014; TR-1123 Protocol. 6. Data on file, Allergan, March 2, 2016; Study Report MD16002-DV.

See More
Natrelle INSPIRA® Silicone-Filled Breast Implants Important Information
Indications
Indicated for women for the following:
  • Breast augmentation for women at least 22 years old for silicone-filled implants. Breast augmentation includes primary breast augmentation to increase breast size, as well as revision surgery to correct or improve the result of a primary breast augmentation surgery.
  • Breast reconstruction. Breast reconstruction includes primary reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality. Breast reconstruction also includes revision surgery to correct or improve the result of a primary breast reconstruction surgery.
Important Safety Information
Contraindications
Breast implant surgery should not be performed in:
  • Women with active infection anywhere in their body.
  • Women with existing cancer or precancer of their breast who have not received adequate treatment for those conditions.
  • Women who are currently pregnant or nursing.
Warnings
  • Breast implants are not lifetime devices or necessarily a one-time surgery.
  • Avoid damage during surgery: Care should be taken to avoid the use of excessive force and to minimize handling of the implant. Use care when using surgical instruments in proximity with the breast implant. For more information, please see the full Directions for Use.
Precautions
Safety and effectiveness have not been established in patients with the following:
  • Autoimmune diseases (eg, lupus and scleroderma).
  • A compromised immune system (eg, currently receiving immunosuppressive therapy).
  • Planned chemotherapy following breast implant placement.
  • Planned radiation therapy to the breast following breast implant placement.
  • Conditions or medications that interfere with wound healing and blood clotting.
  • Reduced blood supply to breast tissue.
  • Clinical diagnosis of depression or other mental health disorders, including body dysmorphic disorder and eating disorders. Please discuss any history of mental health disorders prior to surgery. Patients with a diagnosis of depression, or other mental health disorders, should wait until resolution or stabilization of these conditions prior to undergoing breast implantation surgery.
Adverse Events

Key adverse events are reoperation, implant removal with or without replacement, implant rupture, and capsular contracture Baker Grade III/IV.

Other potential adverse events that may occur with breast implant surgery include: asymmetry, breast pain, breast/skin sensation changes, capsular calcification, delayed wound healing, hematoma, hypertrophic scarring/scarring, implant extrusion, implant malposition, implant palpability/visibility, infection, nipple complications, redness, seroma, swelling, tissue/skin necrosis, wrinkling/rippling.

For more information see the full Directions for Use at www.allergan.com/labeling/usa.htm. To report a problem with Natrelle INSPIRA® Breast Implants, please call Allergan at 1‑800‑433‑8871.

Natrelle INSPIRA® Breast Implants are available by prescription only.